2 links tagged with all of: openevidence + healthtech valuation
Click any tag below to further narrow down your results
Links
This is the second part of an investigation into whether OpenEvidence, a medical AI company valued at $15B, has technology and content worth that price. The author finds the proprietary AI, content ownership, and accuracy claims all look weak under scrutiny.
- OpenEvidence doesn't own its content; publishers can pull their material at any time, which undercuts the moat a buyer would be paying for.
- Accuracy claims collapse outside exam settings: the company's near-perfect USMLE scores drop to about 27% on real-world clinical cases.
- Ad revenue projections ($400M to $500M in 2026) still put the $15B valuation at 30x to 37.5x a single year of sales, and the company's own CEO now pitches drug discovery as the real prize.
A journalist investigates OpenEvidence's $15B valuation after the company signaled openness to acquisition, arguing the "ChatGPT for doctors" startup is worth roughly one-third that amount based on comparable healthtech deals and its claimed $300M ARR.
- OpenEvidence claims $300M in annual recurring revenue but comparable healthtech acquisitions suggest a $500M valuation maximum; founder Daniel Nadler is seeking 30x that amount, relying on his Goldman Sachs network and investor clout to pull it off.
- Livongo's acquisition by Teladoc for $18.5B followed by a $340M writedown serves as a cautionary tale for OpenEvidence's valuation, showing how healthtech M&A can collapse post-acquisition when growth claims don't materialize.
- The author's Part 2 investigation will examine OpenEvidence's actual technology, its lack of proprietary content (publishers can pull it anytime), and accuracy issues ranging from 100% on standardized tests to 27% on real-world medical cases.